RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a leading pharmaceutical company, has announced that it will present seven abstracts at the upcoming American Epilepsy Society (AES) 2023 Annual Meeting. The presentations will focus on the company’s pioneering work with ganaxolone, a novel treatment for refractory seizure disorders.
Marinus will also host a scientific exhibit showcasing a series of posters highlighting the potential of ganaxolone in the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). The exhibition titled, ‘Advancing Ganaxolone Research in Rare Seizure Disorders: Updates from Marinus Pharmaceuticals,’ is scheduled for Monday, December 4, 2023, from 8:00 – 11:00 a.m. in Room W315B.
The Epilepsia publication, “Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: 2-year open-label extension follow-up,” was also highlighted. The study showed that patients continuing treatment with ZTALMY experienced a median 48.2% reduction in major motor seizure frequency, providing supportive evidence for the maintenance of effect in seizures associated with CDD. These results will be presented at AES 2023.
Additionally, preliminary data from a Phase 1 MAD study of a second generation ganaxolone formulation demonstrated linear kinetics through a wide dose range that could allow individualization of treatment in patients with refractory epilepsy. In light of these results, Marinus plans to apply extended-release technologies to the formulation, targeting consistent exposure to achieve once or twice daily dosing while allowing physicians to dose titrate to higher serum concentrations of ganaxolone. The company expects to initiate a clinical trial in Lennox-Gastaut syndrome with a second generation formulation in 2025.
Marinus’s presence at the AES 2023 Annual Meeting underscores its commitment to advancing research in the field of epilepsy. The company’s extensive program of presentations and exhibits will provide attendees with a comprehensive overview of its ongoing work, focusing on the potential of ganaxolone as a transformative treatment for refractory seizure disorders. As Marinus continues to push the boundaries of scientific discovery, the medical community and investors alike eagerly anticipate further updates.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.